glp 1 agonist nash The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis Current Status of Glucagon-like Peptide-1

2024 PMID: 39226030

Back Harris, J (Jan 2022) 'The first insulin injection as a treatment for diabetes', Origins: Current Events in Historical Perspective

Lincoff AM, SELECT Trial Investigators

Although precise hepatic anti-inflammatory mechanisms remain incompletely defined, proposed pathways include reduction of lipotoxicity-induced cellular stress, modulation of hepatic macrophage activity, and direct effects on inflammatory signaling cascades [26]

GLP-1 analog has 97% homology with human GLP-1 and has been approved for the clinical treatment of diabetes and obesity

Especially in American and European regions, at least 50% of residents now weigh more than the international standardized body mass index (BMI) recommends [3]